Twelve year follow-up of a haemophilic cohort.

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Twelve year follow-up of a haemophilic cohort.

Int Conf AIDS. 1992 Jul 19-24;8(1):Mo17 (abstract no. MoC 0062). Unique Identifier : AIDSLINE ICA8/92400022
Lee C; Sabin C; Phillips A; Elford J; Griffiths P; Janossy G; Haemophilia Centre, Royal Free Hospital, London, England.

Abstract: OBJECTIVE: To describe the progression of HIV disease in a haemophilic cohort. METHODS: A longitudinal clinical and laboratory study was conducted in 111 patients from time of first seroconversion in October 1979 until 1st January 1992. RESULTS: 38/111 (34%) have developed AIDS. 39/111 (35%) have died (4 of liver failure including hepatoma). Using Kaplan-Meier plots, the calculated progression to AIDS at 12 years is 45% (95% CI 31-58): if age greater than 25 yrs 63% (95% CI 45-82), age less than 25 yrs 32% (95% CI 15-48, p = 0.0001); CMV+ve 68% (95% CI 48-87), CMV-ve 20% (95% CI 8-32, p = 0.0009). Twelve year progression rate to CD4+ 0.2 is 64% (95% CI 53-76), to CD4+ 0.05 is (53% (95% CI 34-73). 21/34 (62%) patients who are p24 antigen +ve have developed AIDS compared to 17/77 (22%) who are p24 antigen -ve (p = 0.0001). 19/34 (56%) and 20/77 (23%) of those p24 + ve and -ve respectively have died (p = 0.007). Before antiviral and prophylactic treatment for non-AIDS (Nov 88) there were 9 AIDS cases in 3.84 years experience with CD4+ less than 0.05 (1/0.43 yrs) and since treatment 10 AIDS cases in 18.22 years (1/1.8 yrs). CONCLUSION: Age, CMV status and p24 remain strongly predictive of progression. Treatment appears to have reduced the incidence of AIDS. TABULAR DATA, SEE ABSTRACT VOLUME.

Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS/EPIDEMIOLOGY/ PREVENTION & CONTROL Adolescence Adult Antibodies, Viral/IMMUNOLOGY Cohort Studies Cytomegalovirus/IMMUNOLOGY Follow-Up Studies Hemophilia/*COMPLICATIONS/MORTALITY Human HIV Core Protein p24/BLOOD HIV Infections/*COMPLICATIONS/MORTALITY/THERAPY Incidence Life Tables Liver Diseases/COMPLICATIONS/MORTALITY London/EPIDEMIOLOGY Male Predictive Value of Tests Survival Analysis Survival Rate ABSTRACT
921230
M92C5325

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .